My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2025-223
CBCC
>
Official Documents
>
2020's
>
2025
>
2025-223
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
10/27/2025 12:29:35 PM
Creation date
10/27/2025 12:28:42 PM
Metadata
Fields
Template:
Official Documents
Official Document Type
Settlement Agreement
Approved Date
10/07/2025
Control Number
2025-223
Agenda Item Number
9.U.
Entity Name
Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun and Zydus
Subject
Secondary Manufacturers Settlements Participation and Release form
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
7
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
Docusign Envelope ID: A89F5B7A-EA41-4585-AE34-A3E2A4104705 <br />reduce the amount of money for programs to remediate the opioid crisis in its state. <br />Please note, a subdivision will not necessarily directly receive settlement funds by <br />participating; decisions on how settlement funds will be allocated within a state are <br />subject to intrastate agreements or state statutes. <br />You are encouraged to discuss the terms and benefits of the Secondary <br />Manufacturers Settlements with your counsel, your Attorney General's Office, and <br />other contacts within your state. Many states are implementing and allocating funds <br />for this new settlement the same as they did for the prior opioids settlements but <br />states may choose to treat this settlement differently. <br />Information and documents regarding the Secondary Manufacturers Settlements, <br />implementation in your state, and how funds will be allocated within your state can be <br />found on the national settlement website at <br />https://nationalopioidsettlement.com/. This website will be supplemented as <br />additional documents are created. <br />This Participation Packet is different than the participation packet you recently <br />received from Rubris concerning a settlement with Purdue Pharma, L.P, and the <br />Sackler Family. The Secondary Manufacturers Settlements discussed in this <br />Participation Packet are different than the settlement with Purdue and the Sacklers, <br />and you may participate in the Secondary Manufacturers Settlements regardless of <br />whether you join the Purdue and Sackler settlement. <br />How to return signed forms: <br />There are three methods for returning the executed Combined Participation Form and <br />any supporting documentation to the Implementation Administrator: <br />(1) Electronic Signature via DocuSign: Executing the Combined Participation Form <br />electronically through DocuSign will return the signed form to the <br />Implementation Administrator and associate your form with your subdivision's <br />records. Electronic signature is the most efficient method for returning the <br />Combined Participation Form, allowing for more timely participation and the <br />potential to meet higher settlement payment thresholds, and is therefore <br />strongly encouraged. <br />(2)Manual Signature returned via DocuSign: DocuSign allows forms to be <br />downloaded, signed manually, then uploaded to DocuSign and returned <br />automatically to the Implementation Administrator. Please be sure to complete <br />all fields. As with electronic signature, returning a manually signed Combined <br />Participation Form via DocuSign will associate your signed forms with your <br />subdivision's records. <br />(3)Manual Signature returned via electronic mail: If your subdivision is unable to <br />return an executed Combined Participation Form using DocuSign, the signed <br />Combined Participation Form may be returned via electronic mail to <br />opioidsparticipation(c�rubris.com. Please include the name, state, and <br />
The URL can be used to link to this page
Your browser does not support the video tag.